Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical CancerPRNewsWire • 12/23/22
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of MedicinePRNewsWire • 12/21/22
Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferencePRNewsWire • 12/19/22
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic EsophagitisPRNewsWire • 12/16/22
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo NodularisPRNewsWire • 12/15/22
Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 TrialPRNewsWire • 12/12/22
Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple MyelomaPRNewsWire • 12/12/22
Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive YearPRNewsWire • 12/12/22
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASHPRNewsWire • 12/11/22
Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor TypesPRNewsWire • 12/01/22
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 34th Annual Healthcare Conference (Transcript)Seeking Alpha • 11/30/22
Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority ReviewPRNewsWire • 11/30/22
Regeneron Pharmaceuticals, Inc. (REGN) 5th Annual Evercore ISI HealthCONx Conference (Transcript)Seeking Alpha • 11/29/22